Home › Funds › ACUTA CAPITAL PARTNERS, LLC › DSGN
ACUTA CAPITAL PARTNERS, LLC position in DSGN
DESIGN THERAPEUTICS INC · Health Care
ACUTA CAPITAL PARTNERS, LLC reported holding 282,564 shares of DSGN (DESIGN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$4.1M, representing 2.85% of its reported portfolio and ranking #13 among its reported holdings. ACUTA CAPITAL PARTNERS, LLC has disclosed DSGN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ACUTA CAPITAL PARTNERS, LLC's DSGN position evolved
ACUTA CAPITAL PARTNERS, LLC first disclosed a stake in DSGN in Q4 2025 at 150,906 shares (US$1.4M). The position peaked in Q2 2026 at 282,564 shares, worth US$4.1M. Across 3 filings, ACUTA CAPITAL PARTNERS, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 282,564 shares valued at US$4.1M — an increase of 136,664 shares quarter over quarter.. Notable position changes include a 94% increase in Q2 2026 (shares fell 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 150.91K | $1.42M | New |
| Q1 2026 | 145.90K | $1.55M | Reduce |
| Q2 2026 | 282.56K | $4.09M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DSGN and 13F data
DSGN (DESIGN THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in DSGN — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$94.4M), Logos Global Management LP (US$43.4M), BAKER BROS. ADVISORS LP (US$38.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DSGN
- SR ONE CAPITAL MANAGEMENT, LP 6.53M sh · $94.44M · Q2 2026
- Logos Global Management LP 3.00M sh · $43.41M · Q2 2026
- BAKER BROS. ADVISORS LP 2.68M sh · $38.76M · Q2 2026
- Trails Edge Capital Partners, LP 2.00M sh · $28.96M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.81M sh · $26.19M · Q2 2026
- Vivo Capital, LLC 1.61M sh · $23.34M · Q2 2026
- Almitas Capital LLC 1.03M sh · $14.86M · Q2 2026
- Sofinnova Investments, Inc. 865.13K sh · $12.52M · Q2 2026
- KVP Capital Advisors, LP 185.00K sh · $2.68M · Q2 2026
- Elmind Capital, LP 107.90K sh · $1.56M · Q2 2026
More on ACUTA CAPITAL PARTNERS, LLC
FAQ
How long has ACUTA CAPITAL PARTNERS, LLC held DSGN?
ACUTA CAPITAL PARTNERS, LLC has disclosed DSGN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is ACUTA CAPITAL PARTNERS, LLC's current position in DSGN?
As of Q2 2026, ACUTA CAPITAL PARTNERS, LLC holds 282.56K shares of DSGN (DESIGN THERAPEUTICS INC), valued at $4.09M, representing 2.85% of its reported portfolio and ranking #13.
Has ACUTA CAPITAL PARTNERS, LLC been buying or selling DSGN?
In the latest 13F filing (Q2 2026), ACUTA CAPITAL PARTNERS, LLC increased its position in DSGN. The position peaked in Q2 2026 at 282.56K shares.
Which other funds hold DSGN?
Other major institutional holders of DSGN include SR ONE CAPITAL MANAGEMENT, LP, Logos Global Management LP, BAKER BROS. ADVISORS LP, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.